A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

Local Institution - 202, North Melbourne

Local Institution - 201, Melbourne

Local Institution - 106, New York

Local Institution - 113, New York

Local Institution - 102, Cleveland

Local Institution - 111, Oklahoma City

Local Institution - 101, Houston

Local Institution - 110, Denver

Local Institution - 104, Stanford

Local Institution - 105, Boston